MDO 2024 Preliminary Program

  • Scientific program in 3 days
  • Two parallel sessions
  • Two chairmen in each session
  • Poster presentation to each symposium
  • Presentation of a selected young scientist in each session


1. Structure of drug-metabolizing enzymes
2. Xenobiotic metabolism in disease and microbiome in drug metabolism
3. Regulation of drug metabolism and liver regulatory networks impacting drug metabolism
4. Role of ADME genetic variability for personalized medicine
5. Emerging models and OMICS in xenobiotic metabolism
6. Artificial intelligence and modeling in drug metabolism


1.1. Novel structural insights and functions of cytochromes P450
1.2. Mechanisms and dynamics of P450 and other xenobiotic-metabolizing enzymes
1.3. CYPs in endogenous metabolism of lipids and steroids
1.4. Structure and functions of non-cytochrome P450 enzymes and phase II conjugation enzymes in drug metabolism

2.1. Interactions of microbiome on drug metabolism
2.2. Inflammatory regulation of cytochrome P450 enzymes and COVID-19
2.3. Metabolizing enzymes in disease
2.4. Drug metabolizing enzymes, transporters, and nuclear receptors as therapeutic targets

3.1. Nuclear Xenobiotic Receptors: PXR and CAR in metabolism and diseases
3.2. Transcriptional and signaling-based regulation of drug metabolism
3.3. Importance of ncRNAs and lncRNAs in metabolism regulation and liver diseases
3.4. Intestinal and extrahepatic metabolizing enzymes in bioavailability and disposition

4.1. Pharmacogenetics of drug-metabolizing enzymes, epigenetics, and ethnic diversity
4.2. Biomarkers for prediction of drug metabolism and toxicity
4.3. Oligonucleotide and peptide ADME
4.4. Drug transporters and their impact on drug metabolism and disposition

5.1. Novel animal models to predict drug metabolism and toxicity
5.2. 3D experimental models and organ-on-chips in drug metabolism
5.3. Omics and single-cell-based technologies in the study of drug metabolism

6.1. In vitro and in silico systems for prediction of drug metabolism and toxicity/ In vitro to in vivo extrapolation (IVIVE) in drug development
6.2. In silico and PKPB(D) modeling of drug metabolism / Quantitative systems pharmacology (QSP)
6.3. Artificial Intelligence in Drug Safety and Metabolism/ Computational Toxicology and Drug Discovery